4th International conference on phase 1 and early phase clinical trials

March 1-2, 2018 | Hyatt Regency Hong Kong, Tsim Sha Tsui, 18 Hanoi Road, Kowloon, Hong Kong

Dr. Jeffrey Jackson, PhD

Early Asset Development Lead of Integrated Oncology,

Bristol-Myers Squibb, New Jersey, USA


Dr. Jeffrey Jackson is accountable for the development of novel T-cell checkpoint inhibitors and innate immune agonists in the BMS early oncology portfolio (including development strategy, and execution of all studies prior to the initiation of registrational trials. Prior to this, Dr. Jackson was Group Director of the Oncology and Immuno-Oncology Clinical Biomarker function with responsibilities for providing the biomarker strategy and data delivery for Oncology assets from preclinical through lauched products. He was also the Translational R&D lead for Yervoy. Prior to joining BMS in 2009 he spent 17 years at GSK with various responsibilities in drug discovery and early clinical development, primarily in the Oncology therapeutic area. He was responsible for leading several teams that produced clinical development compounds against cell cycle and signal transduction targets.

Dr. Jackson received his PhD in Biology from the University of Rochester where he studied chromatin structure, and completed post-doctoral training in the field of antibody engineering at SmithKline Beecham. His key areas of interest include drug development, cancer genetics, personalized medicine and systems biology.


Day Two: Evolution of Phase 1 Development in Oncology